Literature DB >> 22146617

High-dose chemotherapy with autologous stem cell transplant for breast cancer: what have we learned 25 years later?

Yago Nieto1, Elizabeth J Shpall.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 22146617      PMCID： PMC8223587          DOI： 10.1016/j.bbmt.2011.10.045

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


× No keyword cloud information.
  20 in total

1.  Transplantation of CD34+ peripheral blood cells selected using a fully automated immunomagnetic system in patients with high-risk breast cancer: results of a prospective randomized multicenter clinical trial.

Authors:  S Yanovich; P Mitsky; K Cornetta; R T Maziarz; C Rosenfeld; D S Krause; J P Lotz; J D Bitran; S Williams; R Preti; G Somlo; B Burtness; B Mills
Journal:  Bone Marrow Transplant       Date:  2000-06       Impact factor: 5.483

2.  Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients with advanced refractory malignancies.

Authors:  Yago Nieto; Elizabeth J Shpall; Scott I Bearman; Peter A McSweeney; Pablo J Cagnoni; Steve Matthes; Dan Gustafson; Michael Long; Anna E Barón; Roy B Jones
Journal:  Biol Blood Marrow Transplant       Date:  2005-04       Impact factor: 5.742

3.  High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials.

Authors:  Donald A Berry; Naoto T Ueno; Marcella M Johnson; Xiudong Lei; Jean Caputo; Sjoerd Rodenhuis; William P Peters; Robert C Leonard; William E Barlow; Martin S Tallman; Jonas Bergh; Ulrike A Nitz; Alessandro M Gianni; Russell L Basser; Axel R Zander; R Charles Coombes; Henri Roché; Yutaka Tokuda; Elisabeth G E de Vries; Gabriel N Hortobagyi; John P Crown; Paolo Pedrazzoli; Marco Bregni; Taner Demirer
Journal:  J Clin Oncol       Date:  2011-07-18       Impact factor: 44.544

4.  Soluble Fas (CD95) is a prognostic factor in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous stem cell transplantation.

Authors:  M Bewick; M Conlon; A M Parissenti; H Lee; L Zhang; S Glück; R M Lafrenie
Journal:  J Hematother Stem Cell Res       Date:  2001-12

5.  Acute in vivo resistance in high-dose therapy.

Authors:  B A Teicher; G Ara; S R Keyes; R S Herbst; E Frei
Journal:  Clin Cancer Res       Date:  1998-02       Impact factor: 12.531

6.  The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farber/Beth Israel STAMP program.

Authors:  A D Elias; J Ibrahim; P Richardson; D Avigan; R Joyce; E Reich; M McCauley; C Wheeler; E Frei
Journal:  Biol Blood Marrow Transplant       Date:  2002       Impact factor: 5.742

7.  Prognostic analysis of early lymphocyte recovery in patients with advanced breast cancer receiving high-dose chemotherapy with an autologous hematopoietic progenitor cell transplant.

Authors:  Yago Nieto; Elizabeth J Shpall; Ian K McNiece; Samia Nawaz; Julie Beaudet; Steve Rosinski; Julie Pellom; Victoria Slat-Vasquez; Peter A McSweeney; Scott I Bearman; James Murphy; Roy B Jones
Journal:  Clin Cancer Res       Date:  2004-08-01       Impact factor: 12.531

8.  Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment.

Authors:  E J Shpall; R B Jones; S I Bearman; W A Franklin; P G Archer; T Curiel; M Bitter; H N Claman; S M Stemmer; M Purdy
Journal:  J Clin Oncol       Date:  1994-01       Impact factor: 44.544

9.  High-dose combination alkylating agents with autologous bone marrow support: a Phase 1 trial.

Authors:  W P Peters; J P Eder; W D Henner; S Schryber; D Wilmore; R Finberg; D Schoenfeld; R Bast; B Gargone; K Antman
Journal:  J Clin Oncol       Date:  1986-05       Impact factor: 44.544

10.  Occult tumor contamination of hematopoietic stem-cell products does not affect clinical outcome of autologous transplantation in patients with metastatic breast cancer.

Authors:  B W Cooper; T J Moss; A A Ross; J Ybanez; H M Lazarus
Journal:  J Clin Oncol       Date:  1998-11       Impact factor: 44.544
View more
  1 in total

Review 1.  Circulating tumor cells in breast cancer.

Authors:  Geetha Pukazhendhi; Stefan Glück
Journal:  J Carcinog       Date:  2014-06-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.